At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 33 enrolled
Drug / intervention
FX006 32 mg +1 moredrug
Likely dose
FX006 32 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Double-Blind, Randomized, Parallel Group Comparison of the Effects of FX006 and TCA IR (Triamcinolone Acetonide Suspension) on Blood Glucose in Patients With Osteoarthritis of the Knee and Type 2 Diabetes Mellitus
In Brief
A Phase 2 clinical trial evaluating FX006 32 mg and TCA IR 40 mg for Osteoarthritis of the Knee and Type 2 Diabetes Mellitus. Completed, enrolled 33 participants across 8 sites.
Detailed Summary
The purpose of this study was to compare the effects of FX006 and Triamcinolone Acetonide Injectable Suspension, United States Pharmacopeia (USP) (referred to as TCA IR in the protocol) on blood glucose (BG) in patients with osteoarthritis (OA) of the knee and Type 2 diabetes mellitus (DM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
First PostedMay 2016
Primary CompletionOct 2016
Study CompletionNov 2016
TodayJul 2026
First PostedMay 4, 2016
Enrollment StartApr 1, 2016
Primary CompletionOct 1, 2016
Study CompletionNov 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 10.2 years ago
Interventions
FX006 32 mgdrug
Single 5 mL IA injection
TCA IR 40 mgdrug
Single 1 mL IA injection